Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT01724450
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT01724450
-
- Other papers using this trial's data
- Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT01724450. Randomized; quadruple masking; primary purpose prevention. Start 2013-04 (actual); primary completion 2017-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity
- Acronym
- Ceccy
- Condition
- Breast Cancer
- Condition
- Heart Failure
- Condition
- Cardiotoxicity
- Intervention (Drug)
- Carvedilol
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Sao Paulo
- Collaborator
- Hospital A.C. Camargo
- Collaborator
- Instituto do Cancer do Estado de São Paulo
Record details
- Record id
cardio:ct-nct01724450- Content hash
5322f458c291294c530e4b907cbc79a75ac7468001f41f79705bd700284110a8